Senior Director, Medical Affairs

Confidential Company · India

Senior Director, Medical Affairs

Ocular Surface Programme

Reports to the Chief Executive Officer · Based in India, with recurring in-person presence in the United Arab Emirates

This is a scientific-fidelity role, not a clinical-operations role. Trial execution sits with a contract research organisation. Study design sits with the CEO. This role owns the transmission of the design into the clinic: that investigators understand it, apply it correctly, and that any drift is detected early and escalated — never quietly absorbed

. Design fidelity in the clinic

• Own investigator training on the tissue-state eligibility framework, the structural grading scales, and patientreported outcome administration, across all participating sites and indications.

Investigator, expert and institutional engagement

• Act as principal scientific relationship owner for UAE clinical partners and health-authority stakeholders.
• Sustain and deepen the established investigator relationships in India and Japan.

Evidence and publication strategy

• Own the publication plan for a study intended to be a landmark first-in-human result, and drive it to delivery.
• Set congress and scientific-communication strategy.

Requirements

• Medical degree, with 10+ years in medical affairs and substantial depth in ophthalmology.
• Demonstrated ownership of multi-site, multi-investigator scientific standardisation or diagnostic-competency programmes — at scale, and with measurable outcomes.

Regional medical strategy experience across emerging, Middle East or Asia-Pacific markets

The first twelve months — what success looks like

1. Investigator training and grading calibration complete and documented before first patient in.
2. Measured inter-rater reliability on the structural grading axes across all opening-stage sites, meeting a prespecified threshold.
3. Every eligibility decision documented against the framework; borderline cases escalated, none absorbed.

Publication plan agreed and in motion, with the first outputs scoped